Aclaris Therapeutics, Inc. (ACRS)
4.39
-0.02
(-0.45%)
USD |
NASDAQ |
Oct 02, 16:00
4.395
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics EPS Diluted (Quarterly) : -0.1507 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1507 |
| March 31, 2026 | -0.1539 |
| December 31, 2025 | -0.1614 |
| September 30, 2025 | -0.1192 |
| June 30, 2025 | -0.1259 |
| March 31, 2025 | -0.1232 |
| December 31, 2024 | -1.013 |
| September 30, 2024 | -0.1063 |
| June 30, 2024 | -0.1541 |
| March 31, 2024 | -0.2384 |
| December 31, 2023 | -0.021 |
| September 30, 2023 | -0.4132 |
| June 30, 2023 | -0.4186 |
| March 31, 2023 | -0.4211 |
| December 31, 2022 | -0.4144 |
| September 30, 2022 | -0.2992 |
| June 30, 2022 | -0.3111 |
| March 31, 2022 | -0.3059 |
| December 31, 2021 | -0.3724 |
| September 30, 2021 | -0.3454 |
| June 30, 2021 | -0.3365 |
| March 31, 2021 | -0.5712 |
| Date | Value |
|---|---|
| December 31, 2020 | -0.3022 |
| September 30, 2020 | -0.249 |
| June 30, 2020 | -0.2752 |
| March 31, 2020 | -0.3745 |
| December 31, 2019 | -0.4491 |
| September 30, 2019 | -1.337 |
| June 30, 2019 | -1.208 |
| March 31, 2019 | -0.9107 |
| December 31, 2018 | -0.9946 |
| September 30, 2018 | -1.057 |
| June 30, 2018 | -1.01 |
| March 31, 2018 | -0.98 |
| December 31, 2017 | -0.74 |
| September 30, 2017 | -0.63 |
| June 30, 2017 | -0.56 |
| March 31, 2017 | -0.48 |
| December 31, 2016 | -0.49 |
| September 30, 2016 | -0.50 |
| June 30, 2016 | -0.62 |
| March 31, 2016 | -0.65 |
| December 31, 2015 | -0.28 |
| September 30, 2015 | -5.11 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 0.356 |
| Xeris Biopharma Holdings, Inc. | -0.18 |
| Alumis, Inc. | -1.114 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Veru, Inc. | -0.3032 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.50M |
| Revenue (Quarterly) | 1.629M |
| Total Expenses (Quarterly) | 23.13M |
| Enterprise Value | 524.12M |
| Gross Profit Margin (Quarterly) | 10.80% |
| Profit Margin (Quarterly) | -1.32K% |
| Earnings Yield | -13.33% |
| Normalized Earnings Yield | -13.23 |